

To whom it may concern,

I am writing this letter for the upcoming meeting regarding access for Antipsychotic Medications. I am an outpatient provider that treats severe Mental Illness and many of my patients suffer from Schizophrenia and Bipolar Disorders. When treating these patients' medication is paramount to improve positive outcomes and most importantly to reduce inpatient hospitalizations. However, many of the medications come with serious side effects that could possibly lead to non-compliance and other health comorbidities. There are many new medications that help alleviate those issues but access to them is extremely difficult and very time consuming for my staff. Olanzapine is a very effective medication in treating my severe patients, but it causes a significant amount of weight gain and unfortunately many patients develop elevated blood pressure and Diabetes over long term use. In an effort to help combat weight gain from the use of Olanzapine I was pleased to see the new medication Lybalvi to help offset this issue while controlling my patient's symptoms. Unfortunately, Lybalvi is very difficult to access as they must fail many medications beforehand. It is my hope that Lybalvi access improves so I can have the ability to treat my current patient population as well as a newly diagnosed patient without having to try other medications first.

Kind Regards,

Oluyemisi Adedotun